Taligen Therapeutics: Meeting Milestones

Taligen Therapeutics, Inc. announced that it has successfully attained the development milestone required to trigger the funding of the second tranche of its Series A Preferred financing. The $3.75M Series A is led by Sanderling Ventures, Tango and High Country Venture. The milestone was demonstrated in vivo efficacy of its lead compound TA106.

TA106 is a fragment of a monoclonal antibody which targets a critical regulator of complement activation. The initial development indication for an inhaled version of TA106 is the treatment of severe, persistent asthma. An IND filing for this product is expected in 2007. Taligen is concurrently developing TA106 for other indications.